Gevo Inc. [GEVO] Is Currently -2.79 below its 200 Period Moving Avg: What Does This Mean?

Gevo Inc. [NASDAQ: GEVO] plunged by -$0.05 during the normal trading session on Tuesday and reaching a high of $1.775 during the day while it closed the day at $1.74. The company report on November 8, 2022 that Gevo Reports Third Quarter 2022 Financial Results.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Gevo to Host Conference Call Today at 4:30 p.m. ET.

Gevo Inc. stock has also loss -3.33% of its value over the past 7 days. However, GEVO stock has declined by -23.01% in the 3 months of the year. Over the past six months meanwhile, it has lost -34.34% and lost -59.35% year-on date.

The market cap for GEVO stock reached $405.84 million, with 236.65 million shares outstanding and 230.16 million shares in the current float. Compared to the average trading volume of 7.33M shares, GEVO reached a trading volume of 4540413 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Gevo Inc. [GEVO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GEVO shares is $7.51 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GEVO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

UBS have made an estimate for Gevo Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 14, 2022. While these analysts kept the previous recommendation, Jefferies raised their target price to Hold. The new note on the price target was released on October 19, 2022, representing the official price target for Gevo Inc. stock. Previously, the target price had yet another raise to $5, while Citigroup analysts kept a Buy rating on GEVO stock.

The Average True Range (ATR) for Gevo Inc. is set at 0.14, with the Price to Sales ratio for GEVO stock in the period of the last 12 months amounting to 579.77. The Price to Book ratio for the last quarter was 0.66, with the Price to Cash per share for the same quarter was set at 1.81.

GEVO stock trade performance evaluation

Gevo Inc. [GEVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.33. With this latest performance, GEVO shares dropped by -20.18% in over the last four-week period, additionally sinking by -34.34% over the last 6 months – not to mention a drop of -64.63% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GEVO stock in for the last two-week period is set at 39.22, with the RSI for the last a single of trading hit 36.69, and the three-weeks RSI is set at 40.92 for Gevo Inc. [GEVO]. The present Moving Average for the last 50 days of trading for this stock 2.0926, while it was recorded at 1.7740 for the last single week of trading, and 2.9743 for the last 200 days.

Gevo Inc. [GEVO]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Gevo Inc. [GEVO] shares currently have an operating margin of -6240.79 and a Gross Margin at -1702.39. Gevo Inc.’s Net Margin is presently recorded at -8326.72.

Return on Equity for this stock declined to -17.07, with Return on Assets sitting at -14.46.

Gevo Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 24.30 and a Current Ratio set at 24.50.

Earnings per share (EPS) analysis for Gevo Inc. [GEVO] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GEVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gevo Inc. go to 25.00%.

Gevo Inc. [GEVO]: Insider Ownership positions

There are presently around $190 million, or 51.30% of GEVO stock, in the hands of institutional investors. The top three institutional holders of GEVO stocks are: BLACKROCK INC. with ownership of 25,423,202, which is approximately -0.307% of the company’s market cap and around 2.90% of the total institutional ownership; STATE STREET CORP, holding 25,407,268 shares of the stock with an approximate value of $44.21 million in GEVO stocks shares; and VANGUARD GROUP INC, currently with $21.68 million in GEVO stock with ownership of nearly 13.095% of the company’s market capitalization.

Positions in Gevo Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 77 institutional holders increased their position in Gevo Inc. [NASDAQ:GEVO] by around 15,205,295 shares. Additionally, 53 investors decreased positions by around 22,368,269 shares, while 33 investors held positions by with 71,431,583 shares. The mentioned changes placed institutional holdings at 109,005,147 shares, according to the latest SEC report filing. GEVO stock had 27 new institutional investments in for a total of 5,213,619 shares, while 21 institutional investors sold positions of 6,826,835 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here